Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 1, 1997, Pages 16-22

  Herault J P ^a   Bernat, A ^a   Pflieger, A M ^a   Lormeau, J C ^a   Herbert, J M ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; FONDAPARINUX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; ENZYME INHIBITION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; VEIN THROMBOSIS;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; FACTOR XA; FIBRINOGEN; HUMANS; RABBITS; THROMBOPLASTIN;

EID: 0030772346     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. BENDAYAN, P., BOCCALON, H., DUPOUY, D. AND BONEU, B.: Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low-molecular weight heparins. Thromb. Haemost. 71: 576-80, 1994.
2. BERNAT A., HOFFMANN P., SAINTE-MARIE M. AND HERBERT J. M.: Selective factor Xa inhibition by the synthetic pentasaccharide SR 90107A/Org 31540 potentiates rt-PA-induced venous thrombolysis in rabbits. Fibrinolysis 10: 151-157, 1996.
3. BUCHANAN, M. R., BONEU, B., OFOSU, F. A. AND HIRSH, J., The relative importance of thrombin and factor Xa to the antithrombotic effect of heparin. Blood 65: 198-201, 1985.
4. CADROY, Y., HANSON, S. R. AND HARKER, L. A.: Antithrombotics effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb. Haemost. 70: 631-635, 1993.
5. CARRIÉ, D., CARANOBE, C., SAIVIN, S., HOUIN, G., PETITOU, M. LORMEAU, J. C., VAN BOECKEL, C., MEULEMAN, D. AND BONEU, B.: Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. Blood 84: 2571-2577, 1994.
6. CHIU, H. M., HIRSH, J., YUNG, W. L., REGOEZI, E. AND GENT, M.: Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 49: 171-184, 1977.
7. EISENBERG, P. R., SIEGEL, J. E., ABENDSCHEIN, D. R. AND MILETICH, J. P.: Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J. Clin. Invest. 91: 1877-1883, 1993.
8. FRANCIS C. W., MARKHAM R. E. J., BARLOW G. H., FLORACK T. M. AND MARDER V. J.: Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J. Lab. Clin. Med. 102: 220-230, 1983.
9. HARA T., KUNITADA S. AND IWAMOTO M.: DX-9065A., a synthetic and selective factor Xa inhibitor; species difference in its anticoagulant activity. Thromb. Haemost. 69: 890, 1993.
10. HARA T., YOKOYAMA A., ISHIHARA H., YOKOYAMA Y., NAGAHARA T. AND IWAMOTO M.: DX-9065A., a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb. Haemost. 71: 314-319, 1994.
11. HARA T., YOKOYAMA A., TANABE K., ISHIHARA H. AND IWAMOTO M.: DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb. Haemost. 74: 635-639, 1995.
12. HERBERT, J. M., BERNAT, A., DOL, F., HÉRAULT, J. P., CRÉPON, B. AND LORMEAU, J. C.: DX.-9065A: A novel, synthetic, selective and orally active inhibitor of factor Xa. In vitro and in vivo studies. J. Pharm. Exp. Ther. 276: 1030-1038, 1996.
13. HOGG, P. J. AND JACKSON C. M.: Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc. Nat. Acad. Sci. U.S.A. 86: 3619-3623, 1989.
14. IINO, M., TAKEYA, H., TAKEMITSU, T., NAKAGAKI, T., GABAZZA, E. C. AND SUZUKI, K. Characterization of the binding of factor Xa to fibrinogen/fibrin derivatives and localization site on fibrinogen. Eur. J. Biochem. 232: 90-97, 1995.
15. KATAKURA S., NAGAHARA T., HARA T. AND IWAMOTO M., A.: novel factor Xa inhibitor: Structure-activity relationships and selectivity between factor Xa and thrombin, Biochem. Biophys. Res. Commun. 197: 965-972, 1993.
16. PRAGER, N. A., ABENDSCHEIN, D. R., MCKENZIE, C. R. AND EISENBERG, P. R.: Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 92: 962-967, 1994.
17. ROSING, J., TANS. G., GOVERS-RIEMSLAG, J. W. P., ZWAAL, R. F. A. AND HEMKER, H. C.: The role of phospholipids and factor Va in the prothrombinase complex. J. Biol. Chem. 255: 274-283, 1980.
18. SITKO, G. R., RAMJIT, D. R., STABILITO, I. I. AND LEHMAN, J. J.: Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor. Circulation 85: 805-815, 1992.
19. VALI, Z. AND SCHEGARA, Y.: Localization of the binding site on fibrin for the secondary binding site of thrombin. Biochemistry 27: 1956-1963, 1985.
20. VAN BOECKEL, C. A. A. AND PETITOU, M. THE UNIQUE ANTITHROMBIN III BINDING DOMAIN OF HEPARIN: a Lead to New Synthetic Antithrombotics. Angew. Chem. Int. Ed. Engl. 12: 1671-1690, 1993.
21. WEITZ, J. I., HUDOBA, M., MASSEL, D., MARAGANORE, J. AND HIRSH J.: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86: 385-391, 1990.
22. WILNER G. D., DANITZ M. P., MUDD M. S., HSIEH K. AND FENTON J. W.: Selective immobilization of alpha thrombin by surface-bound fibrin. J. Lab. Clin. Med. 97: 403-411, 1981.